Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  DexCom, Inc.    DXCM

DEXCOM, INC.

(DXCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

DexCom, Inc. : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
02/10/2020 | 09:15am EDT

The company will report its earnings for FY 2019 on 02/13/2020. Generally, the company reports earnings better than estimates. In recent months, the 11 analysts from Standard & Poor's consensus have revised their EPS estimates upward.


© MarketScreener.com 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on DEXCOM, INC.
04/02DEXCOM SCHEDULES FIRST QUARTER 2020 : 30 p.m. Eastern Time
BU
03/30QUALCOMM : Names Heather Ace as Executive Vice President of Human Resources; Exe..
AQ
03/10DEXCOM INC : Change in Directors or Principal Officers (form 8-K)
AQ
03/06How Lipper Award-winning fund managers are playing coronavirus scare
RE
02/24DEXCOM : to Present at Cowen 40th Annual Healthcare Conference
BU
02/20DEXCOM : G6 Continuous Glucose Monitoring (CGM) System Receives CE Mark for Use ..
BU
02/17DEXCOM : G6® CGM System Now Available In Canada
AQ
02/17DEXCOM : and Companion Medical Announce Collaboration to Integrate Dexcom CGM Da..
AQ
02/17DEXCOM : Announces FDA Clearance of New Dexcom G6 Pro CGM
AQ
02/13DEXCOM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
More news
Financials (USD)
Sales 2020 1 750 M
EBIT 2020 227 M
Net income 2020 166 M
Finance 2020 4,07 M
Yield 2020 -
P/E ratio 2020 155x
P/E ratio 2021 96,6x
EV / Sales2020 13,6x
EV / Sales2021 10,9x
Capitalization 23 883 M
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | DXCM | US2521311074 | MarketScreener
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 284,32  $
Last Close Price 260,75  $
Spread / Highest target 26,6%
Spread / Average Target 9,04%
Spread / Lowest Target -29,1%
EPS Revisions
Managers
NameTitle
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Quentin S. Blackford Chief Operating & Financial Officer
Andrew K. Balo EVP-Clinical Affairs, Regulatory Strategies
Jacob Leach Chief Technology Officer
Jay S. Skyler Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DEXCOM, INC.23.12%24 664
MEDTRONIC PLC-17.06%120 856
BAXTER INTERNATIONAL INC.1.57%41 180
HOYA CORPORATION-0.76%32 156
TERUMO CORPORATION-2.34%25 993
ZIMMER BIOMET HOLDINGS-34.57%20 891